

Zhonglin Hao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9401726/publications.pdf>

Version: 2024-02-01

18
papers

1,281
citations

759233

12
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

2465
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanoscintillator-Mediated X-ray Inducible Photodynamic Therapy for In Vivo Cancer Treatment. Nano Letters, 2015, 15, 2249-2256.	9.1	312
2	X-Ray Induced Photodynamic Therapy: A Combination of Radiotherapy and Photodynamic Therapy. Theranostics, 2016, 6, 2295-2305.	10.0	171
3	Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control. Nano Letters, 2017, 17, 862-869.	9.1	167
4	LiGa ₅ O ₈ :Cr-based theranostic nanoparticles for imaging-guided X-ray induced photodynamic therapy of deep-seated tumors. Materials Horizons, 2017, 4, 1092-1101.	12.2	128
5	Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biology, 2012, 33, 723-730.	1.8	108
6	Lenvatinib in Management of Solid Tumors. Oncologist, 2020, 25, e302-e310.	3.7	80
7	Sunitinib: the antiangiogenic effects and beyond. OncoTargets and Therapy, 2016, Volume 9, 5495-5505.	2.0	70
8	Label-free ferrohydrodynamic cell separation of circulating tumor cells. Lab on A Chip, 2017, 17, 3097-3111.	6.0	56
9	Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF- α -Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metabolism, 2018, 28, 228-242.e6.	16.2	54
10	E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Frontiers in Bioscience - Landmark, 2015, 20, 474-490.	3.0	51
11	Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells. Scientific Reports, 2017, 7, 12168.	3.3	31
12	Free Lung Cancer Screening Trends Toward a Twofold Increase in Lung Cancer Prevalence in the Underserved Southeastern United States. Southern Medical Journal, 2017, 110, 188-194.	0.7	15
13	Volasertib for AML: clinical use and patient consideration. OncoTargets and Therapy, 2015, 8, 1761.	2.0	13
14	Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS ONE, 2016, 11, e0157455.	2.5	10
15	Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky. Clinical Lung Cancer, 2021, 22, e911-e920.	2.6	5
16	Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy. Clinical Lung Cancer, 2022, 23, 14-20.	2.6	4
17	Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib. American Journal of Cancer Research, 2014, 4, 135-47.	1.4	4
18	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. BMJ Case Reports, 2016, 2016, bcr2016215304.	0.5	2